PubRank

Gary Maartens

Author PubWeight™ 160.77‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004 11.18
2 Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 2007 6.26
3 Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008 5.94
4 Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa. AIDS 2010 5.46
5 Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006 4.81
6 Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011 4.29
7 Antiretroviral therapy adherence, virologic and immunologic outcomes in adolescents compared with adults in southern Africa. J Acquir Immune Defic Syndr 2009 3.41
8 CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr 2006 3.39
9 Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort. Antivir Ther 2007 3.27
10 Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 2005 3.01
11 Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005 2.91
12 When to initiate highly active antiretroviral therapy in sub-Saharan Africa? A South African cost-effectiveness study. Antivir Ther 2006 2.85
13 Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2010 2.83
14 Pharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapy. PLoS Med 2008 2.82
15 Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults. A qualitative study. J Acquir Immune Defic Syndr 2006 2.77
16 Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009 2.66
17 Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008 2.45
18 Effect of HIV-1 infection on T-Cell-based and skin test detection of tuberculosis infection. Am J Respir Crit Care Med 2006 2.40
19 Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007 2.28
20 Clinical, immunological, and epidemiological importance of antituberculosis T cell responses in HIV-infected Africans. Clin Infect Dis 2007 2.23
21 Mortality in patients treated for tuberculous pericarditis in sub-Saharan Africa. S Afr Med J 2008 2.20
22 Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A 2008 2.03
23 Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited setting. J Acquir Immune Defic Syndr 2011 1.98
24 Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008 1.98
25 Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS 2008 1.85
26 Factors influencing retention in care after starting antiretroviral therapy in a rural South African programme. PLoS One 2011 1.82
27 Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional study. BMC Infect Dis 2008 1.82
28 Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis. PLoS Med 2009 1.81
29 Type 1 helper T cells and FoxP3-positive T cells in HIV-tuberculosis-associated immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2008 1.76
30 Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets. Antimicrob Agents Chemother 2011 1.68
31 Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009 1.66
32 Neurologic manifestations of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome: a case series. Clin Infect Dis 2009 1.62
33 Association of antiretroviral therapy adherence and health care costs. Ann Intern Med 2010 1.57
34 Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registry. BMC Infect Dis 2006 1.54
35 Effect of nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy on dysglycemia and insulin sensitivity in South African HIV-infected patients. J Acquir Immune Defic Syndr 2011 1.52
36 The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 2011 1.49
37 Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin. Br J Clin Pharmacol 2012 1.48
38 Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2007 1.45
39 Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS 2010 1.43
40 The effect of vitamin A and zinc supplementation on treatment outcomes in pulmonary tuberculosis: a randomized controlled trial. Am J Clin Nutr 2010 1.27
41 Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med 2012 1.25
42 Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2009 1.24
43 Effect of antiretroviral therapy on the diagnostic accuracy of symptom screening for intensified tuberculosis case finding in a South African HIV clinic. Clin Infect Dis 2012 1.19
44 Performance of serum C-reactive protein as a screening test for smear-negative tuberculosis in an ambulatory high HIV prevalence population. PLoS One 2011 1.19
45 High prevalence of subtherapeutic plasma concentrations of efavirenz in children. J Acquir Immune Defic Syndr 2007 1.18
46 Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis. Antivir Ther 2011 1.17
47 Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One 2013 1.16
48 Baseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotype. PLoS One 2012 1.15
49 Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis. Am J Respir Crit Care Med 2009 1.09
50 Is it safe to switch between efavirenz and nevirapine in the event of toxicity? Lancet Infect Dis 2007 1.09
51 Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis 2010 1.07
52 A Randomized Controlled Trial of Real-Time Electronic Adherence Monitoring With Text Message Dosing Reminders in People Starting First-Line Antiretroviral Therapy. J Acquir Immune Defic Syndr 2015 1.05
53 Routine cryptococcal antigen screening for HIV-infected patients with low CD4+ T-lymphocyte counts--time to implement in South Africa? S Afr Med J 2011 1.05
54 Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections. BMC Infect Dis 2009 1.03
55 Neuronal toxicity of efavirenz: a systematic review. Expert Opin Drug Saf 2013 1.00
56 Clinical and financial burdens of secondary level care in a public sector antiretroviral roll-out setting (G. F. Jooste Hospital). S Afr Med J 2009 1.00
57 A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother 2012 0.97
58 Global HIV/AIDS Clinical and Translational Pharmacology. AIDS Res Treat 2012 0.96
59 Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa. S Afr Med J 2012 0.95
60 Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype. AIDS 2013 0.94
61 Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infect Dis 2009 0.93
62 Patient-nominated, community-based HIV treatment supporters: patient perspectives, feasibility, challenges, and factors for success in HIV-infected South African adults. AIDS Patient Care STDS 2013 0.93
63 Effect of different antiretroviral drug regimens on body fat distribution of HIV-infected South African women. AIDS Res Hum Retroviruses 2013 0.92
64 Matrix metalloproteinases and tissue damage in HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur J Immunol 2013 0.91
65 Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settings. BMC Health Serv Res 2010 0.89
66 A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa. PLoS One 2013 0.88
67 Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J 2010 0.87
68 HIV infection is associated with a lower incidence of constriction in presumed tuberculous pericarditis: a prospective observational study. PLoS One 2008 0.87
69 Cerebral angioedema associated with enalapril. Br J Clin Pharmacol 2009 0.86
70 Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther 2014 0.86
71 Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. Eur J Clin Pharmacol 2010 0.85
72 Role of the interleukin 10 family of cytokines in patients with immune reconstitution inflammatory syndrome associated with HIV infection and tuberculosis. J Infect Dis 2013 0.85
73 Complications of antiretroviral therapy initiation in hospitalised patients with HIV-associated tuberculosis. PLoS One 2013 0.85
74 Tuberculosis preventive therapy: an underutilised strategy to reduce individual risk of TB and contribute to TB control. S Afr Med J 2014 0.85
75 Pharmacogenomics of HIV therapy: summary of a workshop sponsored by the National Institute of Allergy and Infectious Diseases. HIV Clin Trials 2011 0.84
76 The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy. PLoS One 2012 0.83
77 Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional study. AIDS Res Ther 2010 0.83
78 Mitochondrial genomics and antiretroviral therapy-associated metabolic complications in HIV-infected Black South Africans: a pilot study. AIDS Res Hum Retroviruses 2013 0.82
79 Risk Factors for Incident Diabetes in a Cohort Taking First-Line Nonnucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy. Medicine (Baltimore) 2016 0.82
80 Pitfalls of administering drugs via nasogastric tubes. S Afr Med J 2009 0.81
81 Impact of immune reconstitution inflammatory syndrome on antiretroviral therapy adherence. Patient Prefer Adherence 2012 0.80
82 Acute interstitial nephritis caused by lopinavir/ritonavir in a surgeon receiving antiretroviral postexposure prophylaxis. AIDS 2015 0.80
83 Quantitative and functional differences between peripheral blood myeloid dendritic cells from patients with pleural and parenchymal lung tuberculosis. Clin Vaccine Immunol 2006 0.80
84 Vertical HIV transmission in South Africa: translating research into policy and practice. Lancet 2002 0.79
85 Central nervous system penetration of antiretroviral drugs: pharmacokinetic, pharmacodynamic and pharmacogenomic considerations. Clin Pharmacokinet 2015 0.79
86 Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study. AIDS Res Ther 2012 0.79
87 Adverse Drug Reactions Causing Admission to Medical Wards: A Cross-Sectional Survey at 4 Hospitals in South Africa. Medicine (Baltimore) 2016 0.78
88 Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium. Medicine (Baltimore) 2016 0.78
89 Post-treatment effect of isoniazid preventive therapy on tuberculosis incidence in HIV-infected individuals on antiretroviral therapy. AIDS 2016 0.77
90 Treating AIDS-associated cerebral toxoplasmosis - pyrimethamine plus sulfadiazine compared with cotrimoxazole, and outcome with adjunctive glucocorticoids. S Afr Med J 2007 0.77
91 Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations. Medicine (Baltimore) 2016 0.76
92 Effect of Lopinavir and Nevirapine Concentrations on Viral Outcomes in Protease Inhibitor-experienced HIV-infected Children. Pediatr Infect Dis J 2016 0.75
93 Generic substitution--is it safe in patients at high cardiovascular risk? S Afr Med J 2002 0.75
94 Preventing Paradoxical Tuberculosis-Associated Immune Reconstitution Inflammatory Syndrome in High-Risk Patients: Protocol of a Randomized Placebo-Controlled Trial of Prednisone (PredART Trial). JMIR Res Protoc 2016 0.75
95 Response to "CD4 cell count natural history and informative censoring in sub-Saharan Africa". J Acquir Immune Defic Syndr 2007 0.75
96 Diagnosis and treatment of pulmonary tuberculosis in patients with HIV. Lancet Infect Dis 2012 0.75
97 The Cape Town Clinical Decision Rule for Streptococcal Pharyngitis in Children. Pediatr Infect Dis J 2016 0.75
98 Late efavirenz-induced ataxia and encephalopathy: a case series. J Acquir Immune Defic Syndr 2017 0.75
99 Updated recommendations for the management of upper respiratory tract infections in South Africa. S Afr Med J 2015 0.75
100 Abdominal ultrasound for diagnosing abdominal tuberculosis or disseminated tuberculosis with abdominal involvement in HIV-positive individuals. Cochrane Database Syst Rev 2019 0.75
101 Clinician compliance with laboratory monitoring and prescribing guidelines in HIV-1-infected patients receiving tenofovir. S Afr Med J 2016 0.75
102 The role of the infectious diseases unit at Groote Schuur Hospital in addressing South Africa's greatest burden of disease. S Afr Med J 2012 0.75
103 Gary Maartens--committed to improving public health in South Africa. Lancet Infect Dis 2002 0.75